Benjamin Halladay Esperion Therapeutics, Inc. (ESPR) insider trading activity
Benjamin Halladay is Chief Financial Officer of Esperion Therapeutics, Inc.. Currently has a direct ownership of 474,862 shares of ESPR, which is worth approximately $1.29 Million. The most recent transaction as insider was on Sep 17, 2025, when has been sold 7,046 shares (Common Stock) at a price of $2.81 per share, resulting in proceeds of $19,799. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).
Shares Held (Direct Ownership)
475K
0.08%
3M change
94.67%
12M change
Total Value Held
$1.29 Million
Benjamin Halladay Transaction History
BH
Benjamin Halladay
Chief Financial Officer
Ann Arbor, MI